May 30, 2024

Stream Health Care

It Looks Good On You

Future of heart failure treatment: a global health priority

3 min read


1. Heo S, et al. Quality of life in patients with heart failure: ask the patients. Heart Lung. 2009;38:100-108.

2. Savarese G and Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017; 3: 7-11.

3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211-1259.

4. Bytyçi I and Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol. 2015;15:63-68.

5. Emmons-Bell S, et al. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022;108:1351-1360.

6. Mamas MA, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19:1095-1104.

7. Roger VL, et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics – 2012 Update. Circulation. 2012;125:e2-e220.

8. Chamberlain AM, et al. Multimorbidity in heart failure: a community perspective. Am J Med. 2015;128:38-45.

9. Ergatoudes C, et al. Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry. Clin Res Cardiol. 2019;108): 1025-1033.

10. AstraZeneca. Heart failure. Available at: Accessed August 2023.

11. Lesyuk W, et al. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord. 2018;18:74.

12. Cowie MR, et al. 2014. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 2014;1:110-145.

13. Virani SS, et al. Heart disease and stroke statistics – 2020 update: a report from the American Heart Association. Circulation. 2020;141:e139–e596.

14. Lippi G and Sanchis Gomar F. AME Med J. 2020;5:1-6.

15. Groenewegen A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342-1356.

16. Anderson L, et al. Suspected de novo heart failure in outpatient care: high mortality and morbidity rates (REVOLUTION HF). Abstract presented at: Annual Meeting of the European Society of Cardiology; 30 August – 2 September 2024; London, UK.

17. van Deursen VM, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16:103-111.

18. Sandhu A, et al. Disparity in the setting of incident heart failure. Circ Heart Fail. 2021;14:e008538.

19. Bottle A, et al. Routes to diagnosis of heart failure: observational study using linked data in England. Heart. 2018;104:600-605.

20. Kosaraju A, et al. Left Ventricular Ejection Fraction. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: Accessed April 2024.

21. American Heart Association. Types of heart failure. Available at: Accessed August 2023.

22. Beans C. Inner workings: the race to patch the human heart. Proc Natl Acad Sci U S A. 2018;115:6518-6520.

23. Severino P, et al. Myocardial tissue characterization in heart failure with preserved ejection fraction: from histopathology and cardiac magnetic resonance findings to therapeutic targets. Int J Mol Sci. 2021;22:7650.

24. Ando Y, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.

25. Deichl A, et al. Comorbidities in heart failure with preserved ejection fraction. Herz. 2022;47:301-307.

26. Meier ML and Pierce KN. New therapies for the treatment of heart failure with preserved ejection fraction. Am J Health Syst Pharm. 2022;79:1424-1430.

27. Law S, et al. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Fail. 2020;7:3942-3949.

28. Nativi-Nicolau JN, et al. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785-793.

29. González-López E, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015:36(38);2585-2594.

30. Papingiotis G, et al. Cardiac amyloidosis: epidemiology, diagnosis and therapy. E-Journal of Cardiology Practice. 2021;19.

31. Rozenbaum MH, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10:141-159.


Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.